A Critical Analysis of the Clinical Use of Incretin-Based Therapies: The benefits by far outweigh the potential risks

There is no question that incretin-based glucose-lowering medications have proven to be effective glucose-lowering agents. Glucagon-like peptide 1 (GLP-1) receptor agonists demonstrate an efficacy comparable to insulin treatment and appear to do so with significant effects to promote weight loss wit...

Descripción completa

Detalles Bibliográficos
Autor principal: Nauck, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2013
Materias:
Point-Counterpoint
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687264/
https://www.ncbi.nlm.nih.gov/pubmed/23645884
http://dx.doi.org/10.2337/dc12-2504

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3687264/
https://www.ncbi.nlm.nih.gov/pubmed/23645884
http://dx.doi.org/10.2337/dc12-2504

Ejemplares similares